Effects of dipeptidyl peptidase‐4 inhibition in vivo: Dipeptidyl peptidase‐4 inhibitor/gut microbiome crosstalk suggests novel therapeutic options for diabetes management

• Takuma Yasuda,
• Norio Harada,
• Nobuya Inagaki

Affiliations

Takuma Yasuda

Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine Kyoto University Kyoto Japan

Norio Harada

Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine Kyoto University Kyoto Japan

Nobuya Inagaki

P.I.I.F. Tazuke‐Kofukai Medical Research Institute KITANO HOSPITAL Osaka Japan